Mitsubishi Takes Teneligliptin Patent Appeal To Indian Court
Executive Summary
Japan's Mitsubishi Tanabe has moved a court against Indian patent authorities in a case concerning its patent application relating to certain salts of teneligliptin. The move has set the cat among the pigeons in the Indian market, where cut price versions of the diabetes drug have made strong gains over the recent past, though it's still unclear if the salt patent may have a bearing on these.
You may also be interested in...
Competition Piles Up: 100 Teneligliptin Brands Now In India
A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.
India rejects teneligliptin salts patent
India has rejected Mitsubishi Tanabe's patent application relating to certain salts of teneligliptin, the dipeptidyl peptidase-4 (DPP-4) inhibitor currently in the news after the arrival of a cut-price generic version on the domestic market.
Glenmark 'pioneers' Mitsubishi's teneligliptin in India
Brace yourselves for a potential upsurge in action – both in price and probably elsewhere - in the dipeptidyl peptidase-4 (DPP-4) inhibitor segment in India.